Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled

@article{Matsuda2011SorafenibCO,
  title={Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled},
  author={Yasunobu Matsuda and Manabu Fukumoto},
  journal={Medical Molecular Morphology},
  year={2011},
  volume={44},
  pages={183-189}
}
Hepatocellular carcinoma (HCC) is the most common primary cancer worldwide. The only current drug available for clinical treatment of HCC is sorafenib, which inhibits multiple signaling kinases including Raf family members, platelet-derived growth factor receptor, vascular endothelial growth factor receptors 1 and 2, c-Kit, and Fms-like tyrosine kinase 3. Many studies have revealed that the mechanism underlying the antitumor effect of sorafenib is complex. Because sorafenib inhibits C-Raf more… Expand
Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.
TLDR
TGF-β/ERK/AKT signaling might play a critical role in sorafenib resistance in hepatoma cells, and combination treatment with VPA may be effective against this drug resistance. Expand
Fluoro‐Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery
TLDR
Cells surviving Regorafenib treatment remain viable, but quiescent and capable of regrowth following drug removal, and the reversibility of tumor cell growth suppression after drug removal may have clinical implications. Expand
Sorafenib-Inhibited Signaling: Emerging Evidence of RAFIndependent Pathways as Potential Therapeutic Targets in Hepatocellular Carcinoma
TLDR
Hepatocellular carcinoma is poorly responsive to chemother‐ apeutic drugs and radiotherapy, and effective therapeutic tools for HCC are long-awaited. Expand
Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC
TLDR
This article focuses on platelet factors in clinical HCC and experimental evidence that they provide growth stimulants that can antagonize the growth inhibitory effects of therapy and the mechanisms of multikinase cancer growth inhibitors. Expand
The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition.
TLDR
The data for the first time characterize the impact of sorafenib and regorafen ib on the lipid membrane structure and dynamics, which may contribute to a better understanding of their effectiveness in the treatment of malignancies as well as of their side effects. Expand
HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3
TLDR
The data suggest that HBx shifts the oncogenic addiction of HCC cells to ErbB2/ErbB3 signaling pathway via inducing Erb B3 expression and thereby enhances their sensitivity to EGFR/ErBB2 inhibitors. Expand
Sorafenib/Regorafenib and Phosphatidyl Inositol 3 Kinase/Thymoma Viral Proto-Oncogene Inhibition Interact to Kill Tumor Cells
TLDR
It is demonstrated that the combination of sorafenib family kinase inhibitors with inhibitors of the PI3K/AKT pathway kills tumor cells in vitro and in vivo. Expand
Anti-leprosy drug clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signaling.
TLDR
The previously unknown inhibitory activity of an anti-leprosy drug clofazimine in the Wnt pathway is described and data demonstrating its efficiency in suppressing growth of Wnt-dependent triple-negative breast cancer cells is provided. Expand
Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
TLDR
Preliminary results suggest that selective c‐Met inhibitors have antitumor activity in HCC, with acceptable safety and tolerability in patients with Child‐Pugh A liver function. Expand
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
TLDR
This work reviews the co-inhibitory pathways that are known to suppress intratumoral T cells in HCC and CCA, and suggests alternative immune checkpoints as promising targets. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 75 REFERENCES
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
TLDR
The role of Raf in normal cells and in cancer is discussed, and an overview is given of Raf inhibitors currently in development, focusing on sorafenib tosylate (BAY 43-9006 or sorafeni), the first oral multi-kinase inhibitor developed that targets Raf kinases. Expand
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
TLDR
Examination of cellular signaling pathways showed downregulation of Mcl1 as well as decreased phosphorylation of the STAT3 and MEK/ERK, as potential mechanisms of its anti-tumor effect, which favor further clinical evaluation and development of novel sorafenib combinations. Expand
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
TLDR
Pharmacological inhibition of the MEK/ERK pathway by AZD6244 enhanced the anti-tumor effect of sorafenib in both orthotopic and ectopic models of HCC, and underscore the potential of a combined therapeutic approach with sorAFenib and MEK inhibitors in the treatment of H CC. Expand
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
TLDR
It is suggested that the FTI lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells and may therefore represent an effective alternative for melanoma treatment. Expand
Vitamin K enhancement of sorafenib‐mediated HCC cell growth inhibition in vitro and in vivo
TLDR
Combination of VK1 plus sorafenib strongly induced growth inhibition and apoptosis in rodent and human HCC and inhibited the RAF/mitogen‐activated protein kinase kinase/ERK pathway. Expand
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
TLDR
The results suggest that the antitumor activity of sorafenib in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and signaling-independent mechanisms). Expand
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
TLDR
Ras activation results from several molecular alterations, such as methylation of tumor suppressors and amplification of oncogenes (B-raf). Expand
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives
TLDR
To overcome the resistance to VEGF signaling-targeted MTT, strategies incorporating inhibition of either compensatory pro-angiogenic pathways or recruitment of bone marrow-derived circulating endothelial progenitors, as well as suppression of other oncogenic pathways, are currently being investigated. Expand
Role of RAF/MEK/ERK pathway, p‐STAT‐3 and Mcl‐1 in sorafenib activity in human pancreatic cancer cell lines
TLDR
The results show that sorafenib exerts anti‐proliferative and pro‐apoptotic activity in pancreatic cancer cells and could therefore represent valid treatment for Pancreatic cancer. Expand
Mechanisms of proteasome inhibitor action and resistance in cancer.
  • D. Mcconkey, K. Zhu
  • Biology, Medicine
  • Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • 2008
TLDR
An overview of the current thinking about how PIs may kill cancer cells exemplified for pancreatic cancer and the possible mechanisms involved in resistance to PIs is provided. Expand
...
1
2
3
4
5
...